Review
Applications of gamma-interferon in cancer therapy
Affiliations
- PMID: 1768369
Item in Clipboard
Review
Applications of gamma-interferon in cancer therapy
Mol Biother.
1991 Dec.
Abstract
This review focuses on the use of gamma-interferon (gamma-IFN) in cancer therapy. Although clinical trials using gamma-IFN have yet to identify a treatment niche for this cytokine, these studies have led to a greater understanding of the pleiotropic effects of this molecule on the human immune response, as well as identification of the dose range required for optimal biologic response modification. Thus, continued efforts to clinically develop gamma-IFN are warranted.
Similar articles
-
Interferon-gamma: biologic functions and HCV therapy (type I/II) (1 of 2 parts).Clin Ter. 2006 Jul-Aug;157(4):377-86. Clin Ter. 2006. Retraction in: Clin Ter. 2008 May-Jun;159(3):207. PMID: 17051976 Retracted. Review.
-
Divergent dose-related effects of gamma-interferon therapy on in vitro antibody-dependent cellular and nonspecific cytotoxicity by human peripheral blood monocytes.Cancer Res. 1988 Feb 15;48(4):1042-6. Cancer Res. 1988. PMID: 3123051
-
Phase I evaluation of combination therapy with interleukin 2 and gamma-interferon.Cancer Res. 1991 Aug 1;51(15):3910-8. Cancer Res. 1991. PMID: 1906779 Clinical Trial.
-
The essential role of interferon-gamma during interleukin-12 therapy for murine transitional cell carcinoma of the bladder.J Urol. 2004 Mar;171(3):1336-42. doi: 10.1097/01.ju.0000109751.60921.da. J Urol. 2004. PMID: 14767344
-
[Interferon-alpha].Gan To Kagaku Ryoho. 1988 Apr;15(4 Pt 2-1):797-803. Gan To Kagaku Ryoho. 1988. PMID: 3291773 Review. Japanese.
Cited by
-
Delayed primary excision with subsequent modification of radiotherapy dose for intermediate-risk rhabdomyosarcoma: a report from the Children's Oncology Group Soft Tissue Sarcoma Committee.Int J Cancer. 2015 Jul 1;137(1):204-11. doi: 10.1002/ijc.29351. Epub 2014 Dec 10. Int J Cancer. 2015. PMID: 25418440 Free PMC article.
-
Autologous dendritic cells loaded with antigens from self-renewing autologous tumor cells as patient-specific therapeutic cancer vaccines.Hum Vaccin Immunother. 2023 Dec 31;19(1):2198467. doi: 10.1080/21645515.2023.2198467. Epub 2023 May 3. Hum Vaccin Immunother. 2023. PMID: 37133853 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Other Literature Sources